NCT00740610 - Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2009

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG

GS-9450

GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily

DRUG

GS-9450 Placebo

Placebo to match GS-9450 administered orally once daily

Trial Locations (33)

30309

Atlanta

48109

Ann Arbor

54511

Vandœuvre-lès-Nancy

66160

Kansas City

75020

Paris

75203

Dallas

77555

Galveston

92161

San Diego

Unknown

Tucson

Fresno

Fullerton

San Mateo

Lakewood

Washington D.C.

Jacksonville

Marietta

Chicago

Des Moines

Monroe

New Orleans

Troy

New York

Plainview

Syracuse

Asheville

Durham

Raleigh

Clevleand

Irving

Charlottesville

Falls Church

Richmond

02905

Providence